Gene-therapy in inherited channelopathies like short-QT syndrome: a robust direction towards precision medicine

This editorial refers to ‘AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome’, by S. Nimani et al., https://doi.org/10.1093/eurheartj/ehaf660.Short-QT Syndrome (SQTS) is an inherited channelopathy first described two decades ago. This di...

Full description

Saved in:
Bibliographic Details
Main Authors: Hamdani, Nazha (Author) , Akın, Ibrahim (Author) , El-Battrawy, Ibrahim (Author)
Format: Article (Journal) Editorial
Language:English
Published: 7 January 2026
In: European heart journal
Year: 2026, Volume: 47, Issue: 2, Pages: 214-216
ISSN:1522-9645
DOI:10.1093/eurheartj/ehaf831
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/eurheartj/ehaf831
Get full text
Author Notes:Nazha Hamdani, Ibrahim Akin, and Ibrahim El-Battrawy
Description
Summary:This editorial refers to ‘AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome’, by S. Nimani et al., https://doi.org/10.1093/eurheartj/ehaf660.Short-QT Syndrome (SQTS) is an inherited channelopathy first described two decades ago. This disorder is associated with sudden cardiac death, atrial fibrillation, and bradycardia occurring in childhood
Item Description:Gesehen am 12.01.2026
Physical Description:Online Resource
ISSN:1522-9645
DOI:10.1093/eurheartj/ehaf831